Avexa Announces Results From HIV Drug Study

Australian biotechnology company Avexa reported positive 24-week data from a Phase IIb clinical trial of apricitabine, a potential treatment for HIV.

According to Avexa, the data demonstrate that more than 80 percent of patients treated with apricitabine experienced HIV levels in the blood below detectable levels after 24 weeks. These numbers were better than those patients on the 3TC control.

The company also reported CD4 cell increases of 28 percent to 39 percent and 73 percent to 86 percent in the apricitabine 600- and 800-arms, respectively, compared with the 3TC-treated patients.

No serious adverse events related to apricitabine have occurred and no patients have withdrawn from the trial because of any side effects, the company added.